J. Michael Ruppert
Johns Hopkins University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J. Michael Ruppert.
Oncogene | 2005
K. Wade Foster; Zhaoli Liu; Nail Cd; Xingnan Li; Thomas J. Fitzgerald; Sarah K. Bailey; Andra R. Frost; Iúri Drumond Louro; Tim M Townes; Andrew J. Paterson; Jeffrey E. Kudlow; Susan M. Lobo-Ruppert; J. Michael Ruppert
KLF4/GKLF normally functions in differentiating epithelial cells, but also acts as a transforming oncogene in vitro. To examine the role of this zinc finger protein in skin, we expressed the wild-type human allele from inducible and constitutive promoters. When induced in basal keratinocytes, KLF4 rapidly abolished the distinctive properties of basal and parabasal epithelial cells. KLF4 caused a transitory apoptotic response and the skin progressed through phases of hyperplasia and dysplasia. By 6 weeks, lesions exhibited nuclear KLF4 and other morphologic and molecular similarities to squamous cell carcinoma in situ. p53 determined the patch size sufficient to establish lesions, as induction in a mosaic pattern produced skin lesions only when p53 was deficient. Compared with p53 wild-type animals, p53 hemizygous animals had early onset of lesions and a pronounced fibrovascular response that included outgrowth of subcutaneous sarcoma. A KLF4-estrogen receptor fusion protein showed tamoxifen-dependent nuclear localization and conditional transformation in vitro. The results suggest that KLF4 can function in the nucleus to induce squamous epithelial dysplasia, and indicate roles for p53 and epithelial–mesenchymal signaling in these early neoplastic lesions.
Cancer Biology & Therapy | 2005
Conway C. Huang; Zhaoli Liu; Xingnan Li; Sarah K. Bailey; Nail Cd; K. Wade Foster; Andra R. Frost; J. Michael Ruppert; Susan M. Lobo-Ruppert
KLF4 is induced upon growth-arrest in vitro and during epithelial maturation in vivo, and is essential for proper cell fate specification of post-mitotic cells. In spite of a normal role in post-mitotic cells, expression is upregulated and constitutive in certain tumor types. KLF4 functions as an oncogene in vitro, and enforced expression in basal cells of mouse skin rapidly induces lesions similar to hyperplasia, dysplasia and squamous cell carcinoma (SCC). Here we used conditional expression to characterize early steps in KLF4-mediated tumor initiation. In contrast to SCC-like lesions that result when using a conditional, keratin 14 promoter-dependent strategy, lower conditional expression achieved using a MMTV promoter induced only epidermal cycling within morphologically normal skin, a process we termed occult cell turnover. Surprisingly, KLF4-induced hyperplastic lesions showed increased transgene-derived mRNA and protein in maturing, PCNA-negative cells, a property of endogenous KLF4. In contrast, hyperplastic lesions induced by GLI1, a control, showed uniform transgene expression. In KLF4-induced dysplasia and SCC the complementarity of KLF4 and PCNA was replaced by concordance of the two proteins. These studies show that KLF4 transcripts are normally suppressed in cycling cells in a promoter-independent fashion, consistent with a post-transcriptional control, and reveal loss of this control in the transition from hyperplasia to dysplasia. Like the mouse tumors, human cutaneous SCCs and adjacent dysplasias frequently showed maturation-independence of KLF4, with co-expression of KLF4 and PCNA. A smaller subset of human SCCs showed complementarity of KLF4 and PCNA, similar to hyperplastic mouse skin. The results identify parallels between a mouse model and human primary tumors, and show that successive increases of KLF4 in the nuclei of basal keratinocytes leads to occult cell turnover followed by hyperplasia, dysplasia, and invasive SCC.
Cancer Biology & Therapy | 2008
Wen Jiang; Susan M. Lobo-Ruppert; J. Michael Ruppert
Commentary to: Nuclear Krüppel-like factor 4 expression is associated with human skin squamous cell carcinoma progression and metastasis Yi-Ju Chen, Chun-Ying Wu, Chia-Che Chang, Chieh-Ju Ma, Mu-Chun Li
Science | 1990
Eric R. Fearon; Kathleen R. Cho; Janice M. Nigro; Scott E. Kern; Jonathan W. Simons; J. Michael Ruppert; Stanley R. Hamilton; Antonette C. Preisinger; Giles Thomas; Kenneth W. Kinzler; Bert Vogelstein
Cancer Research | 1993
Jay O. Boyle; John Hakim; Wayne M. Koch; Peter van der Riet; Ralph H. Hruban; R. Arturo Roa; Russell Correo; Yolanda Eby; J. Michael Ruppert; David Sidransky
Cancer Research | 1994
Homaira Nawroz; Peter van der Riet; Ralph H. Hruban; Wayne M. Koch; J. Michael Ruppert; David Sidransky
Cancer Research | 1993
Mirella Gonzalez-Zulueta; J. Michael Ruppert; Kaori Tokino; Yvonne C. Tsai; Charles H. Spruck; Noriomi Miyao; Peter W. Nichols; Gregers G. Hermann; Thomas Horn; Kenneth Steven; Ian C. Summerhayes; David Sidransky; Peter A. Jones
Cancer Research | 1993
J. Michael Ruppert; Kaori Tokino; David Sidransky
Cancer Research | 2002
Iúri Drumond Louro; Evans C. Bailey; Xingnan Li; Lindsey S. South; Peggy McKie-Bell; Bradley K. Yoder; Conway C. Huang; Martin R. Johnson; Aubrey E. Hill; Ronald L Johnson; J. Michael Ruppert
Cancer Research | 1994
Peter van der Riet; Debra Karp; Evan R. Farmer; Qingyi Wei; Lawrence Grossman; Kaori Tokino; J. Michael Ruppert; David Sidransky